Bedrock Bioscience expands Gazelle Chair access for incontinence care

Bedrock Bioscience says the Gazelle Chair, an FDA-cleared ExMI therapy for urinary incontinence and pelvic floor dysfunction, is now available through a growing national provider network. The company is positioning the non-invasive treatment as an alternative to pads, medication and surgery for millions of women living with bladder leakage.

Why it matters: - Bedrock Bioscience is targeting a large unmet need: nearly 62% of adult women in the U.S., or about 78 million, live with urinary incontinence. - The company is pitching the Gazelle Chair as a non-invasive option for women who want to avoid surgery, medication or long-term symptom management. - The treatment is also positioned for pelvic floor dysfunction, a condition tied to pelvic organ prolapse and age-related weakening.

What happened: - Bedrock Bioscience announced the expanded availability of the Gazelle Chair to providers nationwide. - The Gazelle Chair delivers Extracorporeal Magnetic Innervation, or ExMI, for urinary incontinence and pelvic floor dysfunction. - The platform is now offered through a growing network of providers across the country.

The details: - The company says ExMI is FDA-cleared and backed by more than 25 years of published research. - Bedrock Bioscience says the technology has been used to treat more than 15,000 patients over its lifetime. - A patient quoted by the company said she became pad-free after seven sessions and regained the ability to run without fear of leakage. - A Bedrock Bioscience clinical advisor said the goal is to offer women a non-invasive, in-office option with no surgery, no medication and no downtime. - During a session, the patient sits fully clothed while a magnetic field stimulates the pelvic floor muscles. - The treatment uses no skin contact and no anesthesia. - Each session lasts 20 minutes, and patients can resume normal activity immediately afterward. - The company cites a 2020 randomized controlled trial in BioMed Research International that found ExMI improved continence and quality-of-life measures versus standard pelvic floor muscle training. - Bedrock Bioscience points to 46 published ExMI studies listed at gazellechair.com/clinical-studies. - ExMI has two FDA 510(k) clearances and is classified as a Class II powered muscle stimulator. - Each Gazelle Chair is manufactured in the U.S. under ISO-13485 quality standards. - The company says ExMI is not appropriate for every patient. - Contraindications include pregnancy, a copper intrauterine device, ferromagnetic implants, a cardiac pacemaker and severe cardiac arrhythmia. - The company advises patients to review their full medical history with a provider before treatment.

Between the lines: - The launch leans on clinical research and provider access, not consumer wellness branding, to differentiate the device from more familiar incontinence treatments. - The sales pitch is aimed at women who have normalized bladder leakage after childbirth or menopause and at providers looking for a billable in-office option. - The company’s emphasis on no downtime and no anesthesia suggests a push to make the therapy easier to fit into routine outpatient care.

What's next: - Bedrock Bioscience says women can visit gazellechair.com to learn more, review the research and find participating providers. - The company holds the exclusive license to market ExMI under the Gazelle Chair brand to physicians, chiropractors, nurse practitioners, medspas and wellness and longevity facilities. - The expansion sets up broader provider adoption if clinics decide the therapy fits their patient mix and workflow.

The bottom line: - Bedrock Bioscience is betting that an FDA-cleared, in-office magnetic stimulation therapy can win patients and providers looking for a non-surgical answer to a common but under-treated condition.